At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 151 enrolled

Drug / intervention

CYR-064combination

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06019000

NCT06019000Phase 2Completed

A Randomized, Double-Blinded, Placebo-Controlled Trial to Determine The Safety and Efficacy of CYR-064

Cyrano Therapeutics, Inc.·interventional·Posted Aug 31, 2023·Updated Feb 18, 2026

In Brief

A Phase 2 clinical trial evaluating CYR-064 for Hyposmia. Completed, enrolled 151 participants across 14 sites.

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHyposmia

CountriesUnited States

Collaborators--

Phase 2CompletedFinished

202420252026

First PostedAug 2023

Enrollment StartSep 2023

Primary CompletionNov 2025

Study CompletionNov 2025

TodayJul 2026

First PostedAug 31, 2023

Enrollment StartSep 26, 2023

Primary CompletionNov 11, 2025

Study CompletionNov 21, 2025

TodayJul 2, 2026

Enrollment to primary: 2.1 yearsPosted 2.8 years ago

CYR-064combination

CYR-064 is a nasal solution.